Tucatinib - Array BioPharma/Seagen
Alternative Names: ARRY 380; Irbinitinib; MK 7119; ONT 380; TUKYSALatest Information Update: 13 Jul 2024
At a glance
- Originator Array BioPharma
- Developer Array BioPharma; Criterium; Merck & Co; Merck Sharp & Dohme; Novartis; Seagen
- Class 2 ring heterocyclic compounds; Antineoplastics; Diamines; Oxazoles; Pyridines; Quinazolines; Small molecules; Triazoles
- Mechanism of Action ERBB 2 receptor antagonists; Phosphorylation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Colorectal cancer; HER2 positive breast cancer
- Phase II/III Gastrointestinal cancer
- Phase II Biliary cancer; Bladder cancer; Cervical cancer; Endometrial cancer; Gastric cancer; Non-small cell lung cancer; Solid tumours; Urogenital cancer
- Phase I/II Cholangiocarcinoma; Gallbladder cancer
Most Recent Events
- 31 May 2024 Final efficacy and adverse events data from the phase II MOUNTAINEER trial in Colorectal cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 May 2024 Updated efficacy and adverse events data from the phase II BASKET trial in Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 17 Apr 2024 Seagen completes the MOUNTAINEER-02 phase II/III trial in Gastrointestinal cancer (Combination therapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA, Canada, Australia, South Korea, Taiwan, United Kingdom (PO) (NCT04499924)